A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes

• Status: Completed
• Trial end date: 2016-09-13
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of multiple doses of PF-06342674. Several dose levels will be evaluated.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer

Criteria

Inclusion Criteria:

• Women and men age 18 and older.

• Diagnosis of type 1 diabetes within 2 years of randomization.

• Peak stimulated C-peptide levels ≥ 0.15 ng/mL.

Exclusion Criteria:

• Anticipated ongoing use of diabetes medications other than insulin.

• Evidence or history of diabetic complications with significant end-organ damage.

• Episode of severe hypoglycemia within 60 days of randomization.

• Multiple hospitalizations for diabetic ketoacidosis.